Institute of Bioorganic Chemistry  

Medicinal product - antitumor drug Leicladin and technology for producing the substance










Linked profile in other language
Aleksej Yantsevich
+375 17 357 8761
The Institute of Bioorganic Chemistry offers consumers a medicinal product - the antitumor drug Leicladin under a manufacturing agreement, a technology for obtaining a substance under a license agreement, and is looking for partners to conclude a distribution services agreement.
Leucladin (pharmaceutical substance and drug) - a broad-spectrum antitumor drug. One of the most effective drugs for treating patients with hairy cell leukemia, chronic lymphocytic leukemia, non-Hogins lymphoma of low and intermediate grade of malignancy. The drug is also used in the treatment of multiple sclerosis.
Advantages and Innovations
Import substitution technology. In the original domestic technology for the production of Leukladin, the key chemical stages are replaced by enzymatic ones.
Stage of development
Already on the market
Comments regarding stage of development
Tests of Leukladin in clinics of Belarus and Russia have shown its high efficiency in the treatment of a number of oncological diseases, as well as in the treatment of multiple sclerosis. Since 2002, the drug has been successfully used in leading clinics in Belarus and Russia.
Funding source
State budged
IPR status
Exclusive rights
Patents granted
Secret know-how
Comments regarding IPS status
Patent of the Republic of Belarus No. 5602
Sector group

Client information

R&D institution
Year established
NACE keywords
C.21.10 - Manufacture of basic pharmaceutical products
C.21.20 - Manufacture of pharmaceutical preparations
C.20.59 - Manufacture of other chemical products n.e.c.
M.72.19 - Other research and experimental development on natural sciences and engineering
M.74.90 - Other professional, scientific and technical activities n.e.c.
Turnover (in EUR)
Already engaged in transnational cooperation
Additional comments
The institute has an experimental base for studying the biological activity of the obtained compounds at the cellular level and in tests on animal models. For pilot production of the developed products (hemosorbents, preparations of recombinant enzymes, immunochemical reagents, oxyphitosterols, etc.), 5 experimental production sites have been created at the institute.

The results of fundamental and applied research on methods and means of protecting plants from diseases, insects, weeds, and other unfavorable environmental factors that are safe for humans and the biosphere as a whole were the basis for the development of methods for obtaining new plant growth stimulators, pheromone compositions (pheromones of the codling moth LP -U and mill moth), active ingredients of pesticides (analogs of the herbicide Grasp and insecticide Confidor), formulations of pesticides (herbicides, insecticides, fungicides, etc.).

The created intellectual property of the Institute today consists of patents maintained in force, laboratory technological and experimental industrial regulations, technical specifications, and trademarks. Licensing agreements are in force for the transfer of technologies for the production of immunodiagnostic products, hemosorbents, and pesticides to manufacturers.
Languages spoken

Information about partnership

Type of partnership considered
Distribution services agreement
License agreement
Manufacturing agreement
Type and role of partner sought
Consumers interested in purchasing the anticancer drug Leicladin under a manufacturing agreement.

Distributors interested in purchasing the anticancer drug Leicladin under a distribution services agreement.

Partners interested in acquiring technology for obtaining the substance of the anticancer drug Leicladin under a license agreement.
Type and size of partner sought
> 500 MNE
> 500
SME 51-250
SME 11-50
SME <= 10
R&D Institution


Views: 648
Statistics since 26.03.2023 11:04:25